Newly appointed Vice President of Medical Affairs, Europe at BeiGene, Dr Jan-Henrik Terwey, provides exclusive insight on clinical development in the haematology/oncology space, and highlights significant data for its BCL-2 inhibitor, sonrotoclax.
In the past couple of months, BeiGene has experienced regulatory progress for two of its oncology assets in clinical development. The BTK inhibitor BRUKINSA® (zanubrutinib) was recommended by the EMA’s human medicines committee last month. Additionally, the company’s anti-PD-1 antibody achieved EU approval for oesophageal cancer in September 2023.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
According to Data Bridge Market Research, the haematology/oncology market will value $14.83 billion by 2029.1
In this Q&A, Vice President of Medical Affairs, Europe at BeiGene, Dr Jan-Henrik Terwey, covers the upcoming data presentation for the company’s BCL-2 inhibitor sonrotoclax at the upcoming 2023 American Society of Hematology (ASH) meeting, the impact drug shortages are having on clinical trials for haematology/oncology, as well as the major changes he anticipates will impact Europe clinical development within the next five years.
What is the main challenge in advancing a drug through the clinical development process? How can this be overcome?
Developing a new medicine is one of the most R&D-intensive and complex processes across all industries, requiring heavy investment. Clinical trials account for over 90 percent of the cost and time of developing a new medicine.2
One of the challenges that we have in treating cancer is that the human immune system is highly complex. This requires modulating different components of the human immune system in a way that can address different patient segments, as the immune system is dysregulated in different ways across different tumour types.
However, advancements in genomics and molecular profiling allowed for more precise and personalised treatment strategies treating sub-populations of patients with the aim to deliver the right drug to the right patient. While this is great progress, it is also associated with higher complexity regarding clinical trial design and potential regulatory challenges.
Can you share an exciting development of a recent/ongoing BeiGene clinical trial?
… an encouraging 100 percent overall response rate in 56 assessed patients, with no progression [was] reported in our ongoing Phase I/II trial of sonrotocax in combination with zanubrutinib”
Freshly arrived at BeiGene, I am truly excited by our robust and diverse pipeline. From 2024, we anticipate bringing ten new candidates into clinical trials per year, spanning many mechanisms, modalities, and targets, and addressing solid tumour and haematological malignancies.
We have already established a strong foundation in the haematology space with zanubrutinib. BeiGene will be sharing exciting data for two further assets at the upcoming ASH meeting in December 2023: sonrotoclax, our BCL-2 inhibitor, and our BTK-targeted protein degrader, BGB-16673.
One recent highlight for the sonrotoclax development programme includes an encouraging 100 percent overall response rate in 56 assessed patients, with no progression reported, in our ongoing Phase I/II trial of sonrotocax in combination with zanubrutinib in patients with treatment naïve chronic lymphocytic leukaemia /small lymphocytic lymphoma. Based on these data, BeiGene is planning to initiate a pivotal Phase III in this setting.
What is the top consideration for generating valuable evidence in clinical trials?
One key objective in late-stage clinical development is to generate clinical data that supports the assessment of the benefits and risks of a medicine in the population who will ultimately receive the treatment. It is crucial that the subjects studied in clinical trials are sufficiently diverse and representative to inform decision-makers globally and support the clinical case for our treatments in different patient subgroups and well as in diverse health care systems. We are addressing this at BeiGene by delivering a clinical trial footprint that is truly global; our trials run in over 45 countries thereby aiming at supporting more equitable access to healthcare.
What is the primary step the industry can take to mitigate the impact of drug shortages on clinical trials in Europe?
Drug shortages and supply chain issues are a major challenge in the haematology/oncology space for multiple reasons; this is also reflected in clinical trials. We seek to address this by operating our own manufacturing facilities for both small molecule medicines and large molecule biologics to support ongoing clinical research and global commercialisation of our internally developed medicines. It is an area BeiGene is continuing to invest in. We are currently building a flagship US biologics manufacturing and R&D facility in Hopewell, New Jersey to complement BeiGene’s existing capabilities and offer state-of-the art, clinical- and commercial-stage biologics manufacturing.
What are the three main changes you foresee impacting clinical development in Europe in the next three to five years?
[within the next five years] the evolving regulatory landscape will impact clinical development… The introduction of the new Clinical Trials Regulation (CTR) in the European Union, announced in March 2023, is expected to streamline and harmonise clinical trial processes across Member States”
Firstly, I believe that clinical trial designs will become more complex, generating even greater data volume and diversity. We will be tapping into a wider range of rare diseases and demographics.
Secondly, I believe that the evolving regulatory landscape will impact clinical development. Regulatory bodies continuously update their guidelines and processes. The introduction of the new Clinical Trials Regulation (CTR) in the European Union, announced in March 2023, is expected to streamline and harmonise clinical trial processes across Member States.
Thirdly, I think we will be seeing more aspects of digital and technological capabilities entering clinical trial design – the likes of wearable devices and remote monitoring could make clinical trials more patient focused.
About the interviewee
Dr Jan-Henrik Terwey is Vice President of Medical Affairs Europe at BeiGene. Prior to this role, Dr Terwey served as Vice President, Clinical Sciences, and the Global Development Lead for allogeneic CAR-T products at Atara Biotherapeutics. Here, he successfully led the first CAR-T IND approval for Atara. During his tenure at Atara he also served as the Head of Global Medical Affairs and the Head of Cell Therapy Science and Operations. Jan-Henrik previously worked at Amgen for 14 years in roles of increasing responsibility in Medical Affairs, Clinical Operations and Clinical Development in Europe. Jan-Henrik completed his medical degree at Göttingen University, Germany and also studied Philosophy and Political Sciences at Berkeley, USA and in Göttingen, Germany.
References
Hematology Oncology Market. [Internet] Data Bridge Market Research. Year. [cited 2023Nov]. Available from: https://www.databridgemarketresearch.com/reports/global-hematology-oncology-market.
Martin L, Hutchens M, Hawkins C. et al. How much do clinical trials cost? Nat Rev Drug Discov. 2017; 16, 381–382
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.